ResMed Divests MatrixCare for $490 Million

ResMed is offloading its MatrixCare division to private equity firm Frazier Healthcare Partners in an all-cash deal valued at $490 million. The move marks a strategic shift for the medical equipment manufacturer, which plans to funnel the proceeds back to shareholders through an accelerated stock buyback program.

Today, 01:57· Money Talk· 1,868 reads

ResMed Divests MatrixCare for $490 Million

MatrixCare, which specializes in cloud-based electronic health record software for out-of-hospital care, contributed roughly $220 million to ResMed’s $5.1 billion annual revenue for 2025. ResMed CEO Mick Farrell stated the divestiture aligns with the company’s 2030 portfolio management goals. To ensure operational stability, the companies will enter a transition services agreement covering existing systems and daily workflows.

Frazier General Partner Ryan Lucero noted the acquisition aims to improve outcomes within the post-acute care sector. Simultaneously, ResMed disclosed details regarding its recent Noctrix acquisition, which is projected to add $30 million in revenue while impacting fiscal 2027 adjusted earnings per share by 20 cents.

ResMed Divests MatrixCare for $490 Million

Comments (0)